We continue to advance research in immuno-inflammatory diseases such as atopic dermatitis and hidradenitis suppurativa. In addition, we are constantly developing our expertise in non-melanoma skin cancer, like actinic keratosis, basal cell carcinoma and squamous cell carcinoma, and we are exploring the field of rare dermatological diseases with high unmet needs. At Almirall, we have the capacity and experience to drive novel therapies through all phases of research and development up to their regulatory approval. In addition to the above developments, we continue to strengthen our pipeline with new partnerships that will accelerate the discovery and development of new therapies. Pipeline Building a strong pipeline * ex-Greater China ALM27134 Autoimmune dermatology TBD Worldwide Project Indication Expected launch Preclinical phase Phase I Phase II Phase III Under registration Geography Partner ALM223(early stage) Autoimmune dermatology TBD Worldwide* Sarecycline Acne 2024 China Tirbanibulin(extended label) Actinic keratosis US 2024 US Efinaconazole Onychomycosis 2024 EU ALM401 Autoimmune dermatology TBD Worldwide ALM412 Rare dermatological diseases TBD Worldwide EU 2026 EU